GPRC5D and neoplasm: To address the critical issues of heterogeneous expression of target antigens on tumor cells and the downregulation of these antigens during treatment, current research has developed a dual‐specificity CAR‐T cell incorporating both anti‐BCMA and anti‐GPRC5D single‐chain variable fragments.